Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Expands By 175.0%

Portage Biotech Inc. (NASDAQ:PRTG) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 26,400 shares, a growth of 175.0% from the December 31st total of 9,600 shares. Currently, 6.0% of the shares of the stock are short sold. Based on an average daily volume of 639,500 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC bought a new position in shares of Portage Biotech Inc. (NASDAQ:PRTG) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned 1.04% of Portage Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 13.36% of the stock is owned by hedge funds and other institutional investors.

Portage Biotech Trading Down 3.3 %

Shares of NASDAQ:PRTG traded down $0.15 during trading on Friday, reaching $4.41. The company’s stock had a trading volume of 753,853 shares, compared to its average volume of 58,302. Portage Biotech has a 12 month low of $2.10 and a 12 month high of $23.01. The firm’s 50 day simple moving average is $4.65 and its two-hundred day simple moving average is $4.75. The stock has a market capitalization of $4.63 million, a PE ratio of -0.11 and a beta of 1.33.

Portage Biotech (NASDAQ:PRTG) last posted its quarterly earnings data on Tuesday, November 26th. The company reported ($1.26) earnings per share for the quarter. Research analysts anticipate that Portage Biotech will post -13 EPS for the current fiscal year.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.